STAT3 and lung carcinoma: Consequently, treatments based on EGFR inhibition may not be sufficient for the effective treatment of lung-cancer patients with mutant EGFRs and it is necessary to inhibit IL-6/gp130/JAK pathway and further repress STAT3 activity in NSCLC treatment strategy.